Agios $78M C round includes public market investors, as firm grows beyond Celgene
This article was originally published in Scrip
Executive Summary
Agios Pharmaceuticals, a preclinical stage company which aims to be a leader in the emerging field of cancer metabolism, has secured $78 million in an oversubscribed Series C financing – a financing that includes the company’s strategic partner Celgene, existing investors (Arch Venture Partners, Flagship Partners and Third Rock Ventures) and several new undisclosed investors including three leading, large public investment funds.